Extracellular vesicles (EVs) are natural cell-derived membrane-bound nanoparticles containing proteins and nucleic acids, which are newly recognized as the universal agents of intercellular and inter-organismal communication.
EVs are reshaping our perspective on life sciences, environment and public health. They are under intensive investigation as early disease multi-biomarkers, while EV-based personalized therapeutic agents and vaccines have produced enticing results in early-phase clinical trials.
evFOUNDRY targets the unmet knowledge and technology able to streamline production of therapeutic EVs from sustainable sources, drawing the baseline for future EV bioprocessing, which is necessary for effective EV medical translation and opens to new biogenic nanotechnology.
evFOUNDRY has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 801367
